Massachusetts General Hospital — one of the most respected clinical institutions in the country — conducted a study validating the efficacy of The Good Feet Store arch support system. In a category where consumers rank clinical credibility as the #1 close driver, this is a once-in-a-decade asset. It sits today in corporate decks and brand tracker footnotes. It appears in almost none of the customer's journey.
The clinical study is referenced in the Brand Health Tracker, cited in corporate decks, and understood by the strategy team. It is absent from the place that matters: the journey a customer takes from first impression to purchase. Every touchpoint where the claim could do work is a touchpoint where the brand is choosing not to deploy its strongest persuasion asset.
Most brands in this category wish they had an MGH-grade clinical study. The Good Feet Store has one — and most of the customer journey never mentions it. This is not a capability gap. It is an activation gap.
Every number on this page is sourced to a document The Good Feet Store team provided in the RFP package. Nothing here is agency estimation dressed as insight. The evidence is corroborated across three independent sources that triangulate the same conclusion.
Massachusetts General Hospital
Harvard Medical School's primary teaching hospital · #1 US News ranked
A clinical validation from this institution is a tier of credibility competitors in the category cannot match or purchase.
The study is not a manufacturer's white paper. It is a clinical finding from a Harvard-affiliated research hospital — the kind of credibility that pharmaceutical brands spend tens of millions to acquire. The Good Feet Store has it on file. The strategic question is why this is not the single loudest message the brand makes.
Consumer research ranks clinical credibility as the dominant close driver in the category. The product most able to deploy a clinical claim wins the consideration set. The Good Feet Store has the asset. The Good Feet Store is not deploying the asset. The mismatch between what customers weight most and what the brand surfaces most is the core of this observation.
Every other major player in arch-support competes on price, brand, or fit — none carries institutional-grade clinical validation. An MGH reference is a structural competitive moat the category does not currently have. Deploying it moves The Good Feet Store from a specialty-retail brand into an adjacent credibility tier.
Full claim deployment across all eight touchpoints is the goal — but the highest-ROI starting points are not evenly distributed. Three surfaces produce disproportionate close-rate and conversion lift because they appear at the moments when the customer is weighing credibility most actively. Each gets specific, copy-ready example language so execution can begin this quarter, not next strategic cycle.
The landing page is the first moment a prospective customer evaluates whether The Good Feet Store is a real solution or a retail pitch. The MGH reference in the hero — with a visible institutional cue — reframes the entire page from "brand making claims" to "brand validated by authority." It is the single most leverage-dense copy change available.
The existing TV creative ("Back in the Picture," "Caution Tape") performs on the emotional/value axis but does not differentiate The Good Feet Store from generic arch-support claims. A three-second clinical credibility beat — voiceover plus MGH attribution card — moves the brand out of the generic retail category and into a credibility tier the competition cannot reach.
Specialists today reference MGH verbally and inconsistently. A printed one-pager — framed and displayed in each fitting room, plus a take-home card — converts a forgettable verbal mention into a durable artifact the customer can read, consider, and carry home. This is the single highest close-rate intervention because it arrives at the moment of decision.
Only the fitting room references MGH — and only verbally, only inconsistently, only when the specialist remembers. Every other controlled surface in the customer journey is silent on the brand's strongest persuasion asset.
A 5-8 point close-rate lift on claim-exposed cohorts, applied across the system's fitting volume at $1,611 average ticket. Combined with awareness lift from deploying MGH in TV and retargeting, the compound is material in the first twelve months.
As clinical credibility becomes the brand's dominant positioning, The Good Feet Store exits the commoditized retail category and enters an adjacent credibility tier. Lift compounds across unaided awareness (Obs. 02), close rate (Obs. 08), and price-objection resistance.
Most asset-deployment observations require a tradeoff between cost and impact. This one does not. The asset is already paid for. Deployment is standard creative and lifecycle work — a single quarter of disciplined execution.
This is a deployment plan, not a research plan. The asset exists; the job is distributing it across the eight touchpoints that define the customer's journey. Jekyll + Hyde leads creative integration — the work of putting the MGH reference into TV spots and landing pages in a way that feels earned, not pasted. Ryze leads lifecycle deployment — the work of threading the same claim through the nurture sequence, booking confirmation, post-purchase, and retargeting surfaces. Neither agency creates new evidence. Both agencies make the existing evidence visible.
J+H's role on this observation is unusually elevated. The MGH claim lands or fails based on whether it feels earned inside the creative — dropped in awkwardly, it reads as a credential pasted onto a pitch; integrated well, it reframes the entire brand. This is craft work, not tagging work. Every asset J+H touches gets the claim woven into its structural copy, not bolted on at the end.
Ryze owns the deployment of the MGH reference into every surface between booking and register — and owns the measurement infrastructure that tells us which moments produce actual close-rate lift. The same CRM architecture that powers the price-objection work (Obs. 08) provides the cohort segmentation needed to isolate claim-exposure as a variable.
Three primary KPIs drive the intervention and define success. Four supporting KPIs surface the diagnostic detail that tells us why a metric is or isn't moving. All seven feed one shared dashboard that both agencies access and the client owns.
The hard work was done when MGH ran the study. Everything after that is distribution.
Most observations in this document ask for new capability, new investment, or new media. This one does not. The clinical study already exists. The institutional relationship with Massachusetts General already exists. The category's #1 close driver is, by coincidence or by fortune, the asset The Good Feet Store happens to own. What has not yet existed is the work of making that asset visible everywhere the customer decides. Every touchpoint that carries the MGH reference going forward is a touchpoint where the brand is no longer making a claim — it is citing a finding. That is a different kind of conversation with the customer, in a category where every competitor is stuck making claims. The quarterly execution plan on this page turns a file in the corporate drive into the brand's most durable competitive advantage.